Atherosclerosis：大剂量阿托伐他汀可降低血浆CRP水平

2013-01-22 Atherosclerosis CMT 高晓方编译

　　美国学者的一项研究表明，80 mg/天阿托伐他汀可通过显著缩短中位C反应蛋白（CRP）血浆滞留时间降低血浆CRP水平。论文于发表于《动脉粥样硬化》[Atherosclerosis 2013；226（2）：466-470]。　　此项随机、安慰剂对照、双盲、交叉研究共纳入8例混合性高脂血症患者（男性5例，绝经后女性3例）。安慰剂和阿托伐他汀（80 mg/天）治疗8

　　美国学者的一项研究表明，80 mg/天阿托伐他汀可通过显著缩短中位C反应蛋白（CRP）血浆滞留时间降低血浆CRP水平。论文于发表于《动脉粥样硬化》[Atherosclerosis 2013；226（2）：466-470]。

　　此项随机、安慰剂对照、双盲、交叉研究共纳入8例混合性高脂血症患者（男性5例，绝经后女性3例）。安慰剂和阿托伐他汀（80 mg/天）治疗8周后，受试者接受15小时氘化亮氨酸持续预输注。通过亲和层析从脂蛋白缺乏血浆中分离CRP。利用气相色谱-质谱确定同位素富集，并利用房室模型确定动力学参数。

　　结果显示，与安慰剂相比，阿托伐他汀使中位CRP池大小降低28.4%（13.31±3.78对10.26±3.93 mg；P=0.16），与中位CRP部分分解代谢率增加39.9%相关（0.34±0.06对0.50 ± 0.11/天；P=0.09），并未为显著影响中位CRP产生率（0.050±0.01对0.049±0.01 mg/kg/天P=0.78）。

Effects of atorvastatin on human C-reactive protein metabolism

Objective

Statins are known to reduce plasma C-reactive protein (CRP) concentrations. Our goal was to define the mechanisms by which CRP was reduced by maximal dose atorvastatin.

Methods

Eight subjects with combined hyperlipidemia (5 men and 3 postmenopausal women) were enrolled in a randomized, placebo-controlled double-blind, cross over study. Subjects underwent a 15-h primed-constant infusion with deuterated leucine after 8 weeks of placebo and 80 mg/day of atorvastatin. CRP was isolated from lipoprotein deficient plasma, (density > 1.21 g/ml) by affinity chromatography. Isotopic enrichment was determined by gas chromatography/mass spectrometry. Kinetic parameters were determined using compartmental modeling. Paired t test and Wilcoxon signed ranks test were used to compare differences between placebo and atorvastatin.

Results

Compared with placebo, atorvastatin decreased median CRP pool size by 28.4% (13.31 ± 3.78 vs 10.26 ± 3.93 mg; p = 0.16), associated with a median CRP fractional catabolic rate increase of 39.9% (0.34 ± 0.06 vs 0.50 ± 0.11 pools/day; p = 0.09), with no significant effect on median CRP production rate (0.050 ± 0.01 vs 0.049 ± 0.01 mg/kg/day; p = 0.78).

Conclusion

Our data indicate that maximal doses of atorvastatin lower plasma CRP levels by substantially decreasing the median CRP plasma residence time from 2.94 days to 2.0 days, with no significant effect on the median CRP production rate.

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (5)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1947295, encodeId=707c194e29566, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Wed Jul 31 20:51:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783836, encodeId=ac451e838364a, content=<a href='/topic/show?id=4e91528168' target=_blank style='color:#2F92EE;'>#CRP水平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5281, encryptionId=4e91528168, topicName=CRP水平)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Fri Mar 22 07:51:00 CST 2013, time=2013-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269565, encodeId=055c1269565a0, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Thu Jan 24 02:51:00 CST 2013, time=2013-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363878, encodeId=3ad013638e847, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Jan 24 02:51:00 CST 2013, time=2013-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578643, encodeId=241a15e8643f1, content=<a href='/topic/show?id=fbf0436148a' target=_blank style='color:#2F92EE;'>#大剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43614, encryptionId=fbf0436148a, topicName=大剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6a16418535, createdName=ms7899726347904398, createdTime=Thu Jan 24 02:51:00 CST 2013, time=2013-01-24, status=1, ipAttribution=)]
2013-07-31 12498b37m72暂无昵称

#Sclerosis#

67 0
[GetPortalCommentsPageByObjectIdResponse(id=1947295, encodeId=707c194e29566, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Wed Jul 31 20:51:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783836, encodeId=ac451e838364a, content=<a href='/topic/show?id=4e91528168' target=_blank style='color:#2F92EE;'>#CRP水平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5281, encryptionId=4e91528168, topicName=CRP水平)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Fri Mar 22 07:51:00 CST 2013, time=2013-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269565, encodeId=055c1269565a0, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Thu Jan 24 02:51:00 CST 2013, time=2013-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363878, encodeId=3ad013638e847, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Jan 24 02:51:00 CST 2013, time=2013-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578643, encodeId=241a15e8643f1, content=<a href='/topic/show?id=fbf0436148a' target=_blank style='color:#2F92EE;'>#大剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43614, encryptionId=fbf0436148a, topicName=大剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6a16418535, createdName=ms7899726347904398, createdTime=Thu Jan 24 02:51:00 CST 2013, time=2013-01-24, status=1, ipAttribution=)]
2013-03-22 zhangph

#CRP水平#

64 0
[GetPortalCommentsPageByObjectIdResponse(id=1947295, encodeId=707c194e29566, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Wed Jul 31 20:51:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783836, encodeId=ac451e838364a, content=<a href='/topic/show?id=4e91528168' target=_blank style='color:#2F92EE;'>#CRP水平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5281, encryptionId=4e91528168, topicName=CRP水平)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Fri Mar 22 07:51:00 CST 2013, time=2013-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269565, encodeId=055c1269565a0, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Thu Jan 24 02:51:00 CST 2013, time=2013-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363878, encodeId=3ad013638e847, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Jan 24 02:51:00 CST 2013, time=2013-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578643, encodeId=241a15e8643f1, content=<a href='/topic/show?id=fbf0436148a' target=_blank style='color:#2F92EE;'>#大剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43614, encryptionId=fbf0436148a, topicName=大剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6a16418535, createdName=ms7899726347904398, createdTime=Thu Jan 24 02:51:00 CST 2013, time=2013-01-24, status=1, ipAttribution=)]
2013-01-24 rebeccajiejie

#CRP#

53 0
[GetPortalCommentsPageByObjectIdResponse(id=1947295, encodeId=707c194e29566, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Wed Jul 31 20:51:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783836, encodeId=ac451e838364a, content=<a href='/topic/show?id=4e91528168' target=_blank style='color:#2F92EE;'>#CRP水平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5281, encryptionId=4e91528168, topicName=CRP水平)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Fri Mar 22 07:51:00 CST 2013, time=2013-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269565, encodeId=055c1269565a0, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Thu Jan 24 02:51:00 CST 2013, time=2013-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363878, encodeId=3ad013638e847, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Jan 24 02:51:00 CST 2013, time=2013-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578643, encodeId=241a15e8643f1, content=<a href='/topic/show?id=fbf0436148a' target=_blank style='color:#2F92EE;'>#大剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43614, encryptionId=fbf0436148a, topicName=大剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6a16418535, createdName=ms7899726347904398, createdTime=Thu Jan 24 02:51:00 CST 2013, time=2013-01-24, status=1, ipAttribution=)]
2013-01-24 lsndxfj

#ROS#

59 0
[GetPortalCommentsPageByObjectIdResponse(id=1947295, encodeId=707c194e29566, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Wed Jul 31 20:51:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783836, encodeId=ac451e838364a, content=<a href='/topic/show?id=4e91528168' target=_blank style='color:#2F92EE;'>#CRP水平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5281, encryptionId=4e91528168, topicName=CRP水平)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Fri Mar 22 07:51:00 CST 2013, time=2013-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269565, encodeId=055c1269565a0, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Thu Jan 24 02:51:00 CST 2013, time=2013-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363878, encodeId=3ad013638e847, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Jan 24 02:51:00 CST 2013, time=2013-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578643, encodeId=241a15e8643f1, content=<a href='/topic/show?id=fbf0436148a' target=_blank style='color:#2F92EE;'>#大剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43614, encryptionId=fbf0436148a, topicName=大剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6a16418535, createdName=ms7899726347904398, createdTime=Thu Jan 24 02:51:00 CST 2013, time=2013-01-24, status=1, ipAttribution=)]
2013-01-24 ms7899726347904398

#大剂量#

67 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

心血管

Atherosclerosis：大剂量阿托伐他汀可降低血浆CRP水平

相关资讯

科室

工具

服务